<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="bold;} span.year {font-family : courier ; font-style : italic;} Sci" exact="Total" post="EnvironSci. Total EnvironThe Science of the Total Environment0048-96971879-1026Elsevier B.V."/>
 <result pre="{font-family : courier ; font-style : italic;} Sci Total EnvironSci." exact="Total" post="EnvironThe Science of the Total Environment0048-96971879-1026Elsevier B.V. pmcid: 7128376S0048-9697(20)31790-3"/>
 <result pre=": italic;} Sci Total EnvironSci. Total EnvironThe Science of the" exact="Total" post="Environment0048-96971879-1026Elsevier B.V. pmcid: 7128376S0048-9697(20)31790-3 doi: 10.1016/j.scitotenv.2020.138277138277 : Article COVID-19:"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="as the COVID-19 resource centre remains active. Abstract The novel" exact="Coronavirus disease" post="2019 (COVID-19) is caused by SARS-CoV-2, which is the"/>
 <result pre="the COVID-19 resource centre remains active. Abstract The novel Coronavirus" exact="disease" post="2019 (COVID-19) is caused by SARS-CoV-2, which is the"/>
 <result pre="SARS-CoV-2, which is the causative agent of a potentially fatal" exact="disease" post="that is of great global public health concern. The"/>
 <result pre="SARS, MERS and common flu; the probable mechanism behind the" exact="infection" post="and its immune response. Further, the current treatment options,"/>
 <result pre="Converting Enzyme 2 Fc ADAM17, ADAM metallopeptidase domain 17 ARDS," exact="acute respiratory distress syndrome" post="ASC, Apoptosis-associated speck-like protein containing a CARD CNS, Central"/>
 <result pre="Enzyme 2 Fc ADAM17, ADAM metallopeptidase domain 17 ARDS, acute" exact="respiratory" post="distress syndrome ASC, Apoptosis-associated speck-like protein containing a CARD"/>
 <result pre="Fc ADAM17, ADAM metallopeptidase domain 17 ARDS, acute respiratory distress" exact="syndrome" post="ASC, Apoptosis-associated speck-like protein containing a CARD CNS, Central"/>
 <result pre="distress syndrome ASC, Apoptosis-associated speck-like protein containing a CARD CNS," exact="Central Nervous System" post="COVID-19, coronavirus disease 2019 ER, endoplasmic reticulum ExoN, exoribonuclease"/>
 <result pre="syndrome ASC, Apoptosis-associated speck-like protein containing a CARD CNS, Central" exact="Nervous System" post="COVID-19, coronavirus disease 2019 ER, endoplasmic reticulum ExoN, exoribonuclease"/>
 <result pre="speck-like protein containing a CARD CNS, Central Nervous System COVID-19," exact="coronavirus disease" post="2019 ER, endoplasmic reticulum ExoN, exoribonuclease FDA, Food and"/>
 <result pre="protein containing a CARD CNS, Central Nervous System COVID-19, coronavirus" exact="disease" post="2019 ER, endoplasmic reticulum ExoN, exoribonuclease FDA, Food and"/>
 <result pre="Administration FP, internal fusion protein HCoV, Human coronavirus HIV, human" exact="immunodeficiency" post="virus JAK-STAT, Janus kinase/signal transducer and activator of transcription"/>
 <result pre="and activator of transcription JNK, c-Jun N- terminal kinase MCP-1," exact="Monocyte" post="chemoattractant protein-1 MERS, Middle East respiratory syndrome MERS-CoV, Middle"/>
 <result pre="N- terminal kinase MCP-1, Monocyte chemoattractant protein-1 MERS, Middle East" exact="respiratory" post="syndrome MERS-CoV, Middle East respiratory syndrome coronavirus MHV, mouse"/>
 <result pre="terminal kinase MCP-1, Monocyte chemoattractant protein-1 MERS, Middle East respiratory" exact="syndrome" post="MERS-CoV, Middle East respiratory syndrome coronavirus MHV, mouse hepatitis"/>
 <result pre="chemoattractant protein-1 MERS, Middle East respiratory syndrome MERS-CoV, Middle East" exact="respiratory" post="syndrome coronavirus MHV, mouse hepatitis virus mRNA, messenger RNA"/>
 <result pre="protein-1 MERS, Middle East respiratory syndrome MERS-CoV, Middle East respiratory" exact="syndrome" post="coronavirus MHV, mouse hepatitis virus mRNA, messenger RNA NF-kB,"/>
 <result pre="respiratory syndrome MERS-CoV, Middle East respiratory syndrome coronavirus MHV, mouse" exact="hepatitis" post="virus mRNA, messenger RNA NF-kB, Nuclear Factor kappa-light-chain-enhancer of"/>
 <result pre="Ribonucleic acid ROS, Reactive oxygen species RTC, replicase-transcriptase complex SARS," exact="Severe" post="acute respiratory syndrome SARS-COV-2, Severe acute respiratory syndrome coronavirus-2"/>
 <result pre="acid ROS, Reactive oxygen species RTC, replicase-transcriptase complex SARS, Severe" exact="acute" post="respiratory syndrome SARS-COV-2, Severe acute respiratory syndrome coronavirus-2 TM,"/>
 <result pre="ROS, Reactive oxygen species RTC, replicase-transcriptase complex SARS, Severe acute" exact="respiratory" post="syndrome SARS-COV-2, Severe acute respiratory syndrome coronavirus-2 TM, transmembrane"/>
 <result pre="Reactive oxygen species RTC, replicase-transcriptase complex SARS, Severe acute respiratory" exact="syndrome" post="SARS-COV-2, Severe acute respiratory syndrome coronavirus-2 TM, transmembrane TMPRSS11a,"/>
 <result pre="species RTC, replicase-transcriptase complex SARS, Severe acute respiratory syndrome SARS-COV-2," exact="Severe" post="acute respiratory syndrome coronavirus-2 TM, transmembrane TMPRSS11a, Transmembrane serine"/>
 <result pre="RTC, replicase-transcriptase complex SARS, Severe acute respiratory syndrome SARS-COV-2, Severe" exact="acute" post="respiratory syndrome coronavirus-2 TM, transmembrane TMPRSS11a, Transmembrane serine protease"/>
 <result pre="replicase-transcriptase complex SARS, Severe acute respiratory syndrome SARS-COV-2, Severe acute" exact="respiratory" post="syndrome coronavirus-2 TM, transmembrane TMPRSS11a, Transmembrane serine protease 11a"/>
 <result pre="complex SARS, Severe acute respiratory syndrome SARS-COV-2, Severe acute respiratory" exact="syndrome" post="coronavirus-2 TM, transmembrane TMPRSS11a, Transmembrane serine protease 11a TNFβ,"/>
 <result pre="syndrome coronavirus-2 TM, transmembrane TMPRSS11a, Transmembrane serine protease 11a TNFβ," exact="Tumor" post="necrosis factor β TRAF3, TNF receptor associated factor 3"/>
 <result pre="3 TRS, transcriptional regulatory sequence WHO, World Health Organization Keywords" exact="Coronavirus disease" post="2019 (COVID-19) SARS-CoV-2 Mechanism of action Therapeutic approach Indian"/>
 <result pre="TRS, transcriptional regulatory sequence WHO, World Health Organization Keywords Coronavirus" exact="disease" post="2019 (COVID-19) SARS-CoV-2 Mechanism of action Therapeutic approach Indian"/>
 <result pre="Indian traditional medicine Editor: Damia Barcelo 1 Introduction The novel" exact="coronavirus disease" post="2019 (COVID-19), caused by the Severe acute respiratory syndrome"/>
 <result pre="traditional medicine Editor: Damia Barcelo 1 Introduction The novel coronavirus" exact="disease" post="2019 (COVID-19), caused by the Severe acute respiratory syndrome"/>
 <result pre="Introduction The novel coronavirus disease 2019 (COVID-19), caused by the" exact="Severe" post="acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is in the midst"/>
 <result pre="The novel coronavirus disease 2019 (COVID-19), caused by the Severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), is in the midst of"/>
 <result pre="novel coronavirus disease 2019 (COVID-19), caused by the Severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), is in the midst of worldwide"/>
 <result pre="coronavirus disease 2019 (COVID-19), caused by the Severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), is in the midst of worldwide panic"/>
 <result pre="can be penned down for their role in defeating this" exact="viral" post="transmission. At a time of worldwide anxiety, it is"/>
 <result pre="the structure, immunological influence, mechanism of action of the SARS-CoV-2" exact="infection" post="in the human host cell, the availability of disease-specific"/>
 <result pre="SARS-CoV-2. 2 A brief overview of coronavirus Coronaviruses, having a" exact="total" post="of 39 species under the broad realm of Riboviria,"/>
 <result pre="et al., 2020). All the SARS-CoV fall under the species" exact="Severe" post="acute respiratory syndrome-related coronavirus and genus Beta-coronavirus. Most of"/>
 <result pre="al., 2020). All the SARS-CoV fall under the species Severe" exact="acute" post="respiratory syndrome-related coronavirus and genus Beta-coronavirus. Most of the"/>
 <result pre="2020). All the SARS-CoV fall under the species Severe acute" exact="respiratory" post="syndrome-related coronavirus and genus Beta-coronavirus. Most of the species"/>
 <result pre="OC43 (HCoV-OC43), Human coronavirus (HCoV-HKU1), SARS-CoV, SARS-CoV-2 and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), belong to the beta-coronavirus genus. HCoV-229E,"/>
 <result pre="(HCoV-OC43), Human coronavirus (HCoV-HKU1), SARS-CoV, SARS-CoV-2 and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), belong to the beta-coronavirus genus. HCoV-229E, HCoV-NL63,"/>
 <result pre="HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 strains of coronavirus cause mild" exact="respiratory" post="diseases in humans. The SARS-CoV-2 is a zoonotic virus"/>
 <result pre="has spread from human-to-human. Human coronaviruses are predominantly concomitant with" exact="upper" post="respiratory tract illnesses ranging from mild to moderate including"/>
 <result pre="spread from human-to-human. Human coronaviruses are predominantly concomitant with upper" exact="respiratory" post="tract illnesses ranging from mild to moderate including common"/>
 <result pre="SARS-CoV and MERS-CoV are the two major causes of severe" exact="pneumonia" post="in human (Song et al., 2019). A comparative analysis"/>
 <result pre="infection. The WHO, on February 11, 2020, officially named the" exact="viral" post="disease COVID-19 (Jiang et al., 2020; Guarner, 2020). The"/>
 <result pre="The WHO, on February 11, 2020, officially named the viral" exact="disease" post="COVID-19 (Jiang et al., 2020; Guarner, 2020). The Coronavirus"/>
 <result pre="predecessor SARS-CoV first emerged in 2002. During its course of" exact="infection" post="from 2002 to 2003, 774 deaths were recorded out"/>
 <result pre="to 2003, 774 deaths were recorded out of the 8000+" exact="infections" post="spread across 37 countries (Peiris et al., 2004). This"/>
 <result pre="2 weeks. During this time the virus replicates in the" exact="upper" post="and lower respiratory tract, forming lesions (Chan et al.,"/>
 <result pre="During this time the virus replicates in the upper and" exact="lower" post="respiratory tract, forming lesions (Chan et al., 2020b). The"/>
 <result pre="this time the virus replicates in the upper and lower" exact="respiratory" post="tract, forming lesions (Chan et al., 2020b). The general"/>
 <result pre="In the advanced stage, the symptoms of this virus show" exact="pneumonia" post="which progresses to severe pneumonia and acute respiratory distress"/>
 <result pre="symptoms of this virus show pneumonia which progresses to severe" exact="pneumonia" post="and acute respiratory distress syndrome (ARDS) which results in"/>
 <result pre="this virus show pneumonia which progresses to severe pneumonia and" exact="acute respiratory distress syndrome" post="(ARDS) which results in to the need for life-support"/>
 <result pre="virus show pneumonia which progresses to severe pneumonia and acute" exact="respiratory" post="distress syndrome (ARDS) which results in to the need"/>
 <result pre="pneumonia which progresses to severe pneumonia and acute respiratory distress" exact="syndrome" post="(ARDS) which results in to the need for life-support"/>
 <result pre="Symptomatic comparison of COVID-19, SARS, MERS and Common. Table 1" exact="Diseases" post="Symptoms Onset of disease Incubation period Recovery Transmission of"/>
 <result pre="SARS, MERS and Common. Table 1 Diseases Symptoms Onset of" exact="disease" post="Incubation period Recovery Transmission of disease Complications if any"/>
 <result pre="Diseases Symptoms Onset of disease Incubation period Recovery Transmission of" exact="disease" post="Complications if any Treatments if available Novel Coronavirus (COVID-19)"/>
 <result pre="Sudden 2–14 days after exposure 2–8 weeks Human to Human" exact="Acute" post="pneumonia, septic shock, respiratory failure in adverse condition. No"/>
 <result pre="days after exposure 2–8 weeks Human to Human Acute pneumonia," exact="septic shock," post="respiratory failure in adverse condition. No vaccines available, only"/>
 <result pre="exposure 2–8 weeks Human to Human Acute pneumonia, septic shock," exact="respiratory" post="failure in adverse condition. No vaccines available, only symptoms"/>
 <result pre="adverse condition. No vaccines available, only symptoms can be treated." exact="Severe" post="Acute Respiratory Syndrome (SARS) FeverDry CoughHeadacheDifficulty in breathingMuscle achesLoss"/>
 <result pre="condition. No vaccines available, only symptoms can be treated. Severe" exact="Acute" post="Respiratory Syndrome (SARS) FeverDry CoughHeadacheDifficulty in breathingMuscle achesLoss of"/>
 <result pre="No vaccines available, only symptoms can be treated. Severe Acute" exact="Respiratory" post="Syndrome (SARS) FeverDry CoughHeadacheDifficulty in breathingMuscle achesLoss of appetiteDiarrhoea"/>
 <result pre="vaccines available, only symptoms can be treated. Severe Acute Respiratory" exact="Syndrome" post="(SARS) FeverDry CoughHeadacheDifficulty in breathingMuscle achesLoss of appetiteDiarrhoea Sudden"/>
 <result pre="after exposure 5–6 weeks Human to Human Heart, Liver and" exact="Respiratory" post="failure in adverse condition. Breathing ventilator to deliver oxygen.Pneumonia"/>
 <result pre="oxygen.Pneumonia treating antibioticsAntiviral medicinesSteroids to reduce lung swelling Middle East" exact="Respiratory" post="Syndrome (MERS) FeverChillsDiarrhoeaNauseaVomitingCongestionSneezingSore throat Sudden 5–6 days after exposure"/>
 <result pre="treating antibioticsAntiviral medicinesSteroids to reduce lung swelling Middle East Respiratory" exact="Syndrome" post="(MERS) FeverChillsDiarrhoeaNauseaVomitingCongestionSneezingSore throat Sudden 5–6 days after exposure 6–7"/>
 <result pre="Sudden 5–6 days after exposure 6–7 weeks Human to Human" exact="Acute" post="pneumonia Kidney failure in adverse condition. Treatment only for"/>
 <result pre="5–6 days after exposure 6–7 weeks Human to Human Acute" exact="pneumonia" post="Kidney failure in adverse condition. Treatment only for symptoms"/>
 <result pre="days after exposure 6–7 weeks Human to Human Acute pneumonia" exact="Kidney" post="failure in adverse condition. Treatment only for symptoms such"/>
 <result pre="treated by medication. This table represents the parallel investigation of" exact="Severe" post="Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS),"/>
 <result pre="by medication. This table represents the parallel investigation of Severe" exact="Acute" post="Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Novel"/>
 <result pre="medication. This table represents the parallel investigation of Severe Acute" exact="Respiratory" post="Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Novel Coronavirus"/>
 <result pre="This table represents the parallel investigation of Severe Acute Respiratory" exact="Syndrome" post="(SARS), Middle East Respiratory Syndrome (MERS), Novel Coronavirus (COVID-19)"/>
 <result pre="parallel investigation of Severe Acute Respiratory Syndrome (SARS), Middle East" exact="Respiratory" post="Syndrome (MERS), Novel Coronavirus (COVID-19) and Common Flu with"/>
 <result pre="investigation of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory" exact="Syndrome" post="(MERS), Novel Coronavirus (COVID-19) and Common Flu with their"/>
 <result pre="nucleocapsid protein, which are required to regulate the function and" exact="viral" post="structure (Schoeman and Fielding, 2019). Among these four proteins"/>
 <result pre="helps the virus to develop the capsid and the entire" exact="viral" post="structure appropriately and the later one helps in the"/>
 <result pre="are, the large ectodomain, a single-pass transmembrane anchor and a" exact="short" post="intracellular tail. These play a major role in anchoring"/>
 <result pre="domain (RBD) and the receptor binding motif (RBM) in the" exact="viral" post="genome (Yin and Wunderink, 2018; Zhang et al., 2020;"/>
 <result pre="but medics in Wuhan have suggested the likelihood that the" exact="disease" post="can affect the production of sperm leading to low"/>
 <result pre="the disease can affect the production of sperm leading to" exact="low sperm count" post="and the formation of male sex hormones (low libido)."/>
 <result pre="ACE2 receptors leading to COVID-19 related pneumonia, while also causing" exact="acute" post="myocardial injury and chronic damage to the cardiovascular system"/>
 <result pre="COVID-19 related pneumonia, while also causing acute myocardial injury and" exact="chronic" post="damage to the cardiovascular system (Zheng et al., 2020)."/>
 <result pre="also causing acute myocardial injury and chronic damage to the" exact="cardiovascular" post="system (Zheng et al., 2020). Interestingly, it has also"/>
 <result pre="has also been proposed that SARS-CoV-2 mechanism of action in" exact="infection" post="of humans is similar to the SARS. It has"/>
 <result pre="residue (Gln493) that favours the attachment and fusion of the" exact="viral" post="S protein with virus into the ACE2 protein of"/>
 <result pre="especially the one present in the lungs which results in" exact="respiratory" post="infections in humans (Zhao et al., 2020; Yin and"/>
 <result pre="the one present in the lungs which results in respiratory" exact="infections" post="in humans (Zhao et al., 2020; Yin and Wunderink,"/>
 <result pre="knowledge about the receptors and its targets and basis of" exact="viral" post="replication would be a stepping stone to find a"/>
 <result pre="targets and basis of viral replication would be a stepping" exact="stone" post="to find a remedy for the SARS-CoV-2 infection. Fig."/>
 <result pre="figure depicts the structure of the COVID-19 virus. Among the" exact="viral" post="structure the S protein has a major role in"/>
 <result pre="S2 subunit internalises and creates the membrane fusion among the" exact="viral" post="subunit and the ACE2 receptors. This leads to the"/>
 <result pre="the ACE2 receptors. This leads to the release of the" exact="viral" post="RNA into the host cell and results into respiratory"/>
 <result pre="the viral RNA into the host cell and results into" exact="respiratory" post="infection. 4 Replication of SARS-CoV-2 After the SARS-CoV-2 virus"/>
 <result pre="next step for its survival is its RNA replication. The" exact="viral" post="RNA replication is the most unusual and critical step"/>
 <result pre="but also attacks the immune system of the host during" exact="viral" post="replication (Youngchang et al., 2020). Further these Nsp proteins"/>
 <result pre="known as the building block for the production of new" exact="viral" post="particles inside the host body, while the positive stranded"/>
 <result pre="a helical twisted structure and buds into the ER lumen." exact="Viral" post="progenies are transferred to the cell membranes by the"/>
 <result pre="could enable us to develop a strategy to overcome this" exact="viral infection." post="Other than replication, other pathways associated with the virus"/>
 <result pre="cell. SARS-CoV-2 binds to same ACE2 receptor present in the" exact="respiratory" post="epithelium and alveoli of the lungs (Liu et al.,"/>
 <result pre="cleaved and shed by ADAM17 into the extra membrane space." exact="Reduced" post="ACE2 has been known to be concomitant with alveoli"/>
 <result pre="been known to be concomitant with alveoli injury and increases" exact="pulmonary" post="vascular permeability (Li and Clercq, 2020). This could be"/>
 <result pre="known to be concomitant with alveoli injury and increases pulmonary" exact="vascular" post="permeability (Li and Clercq, 2020). This could be due"/>
 <result pre="II stimulated ATIR results in the lung pathology associated with" exact="respiratory" post="distress (Li and Clercq, 2020). Once the virus translates"/>
 <result pre="these pathways combined together cause a cytokine storm resulting in" exact="respiratory" post="distress a common symptom of COVID-19. Another pathway involved"/>
 <result pre="the proteins that are analogous in both viruses. During the" exact="infection" post="of the virus, the most important part is the"/>
 <result pre="resulting in an increased amount of Angiotensin II leading to" exact="respiratory" post="distress. Upon binding, the virus fuses with the membrane"/>
 <result pre="cytokine. This results in a cytokine storm, further resulting in" exact="respiratory" post="distress. 6 SARS-CoV-2 and the immune system The HCoVs"/>
 <result pre="not yet clear how SARS-CoV-2 affects the immune system. During" exact="viral infection," post="host factors elicits immune response against the viruses. T"/>
 <result pre="cells. The CD8+ T cells account for about 80% of" exact="total" post="inflammatory cells in the pulmonary interstitium in SARS-CoV infected"/>
 <result pre="account for about 80% of total inflammatory cells in the" exact="pulmonary" post="interstitium in SARS-CoV infected patients and play a critical"/>
 <result pre="2014). The cytokines, IL-17 recruit monocytes and neutrophils to the" exact="infection" post="site showing inflammation and activates other downstream cascades of"/>
 <result pre="induced by a novel BH3-like region located in the C-terminal" exact="cytosolic" post="domain of SARS-CoV protein mediated by Bcl-xL (Yang et"/>
 <result pre="for designing new drugs and vaccines for SARS-CoV-2 composed of" exact="viral" post="structural proteins, which can induce dominant, effective, and long-term"/>
 <result pre="of HCoVs The COVID-19 are not always confined to the" exact="respiratory" post="tract, but they also invade the Central Nervous System"/>
 <result pre="confined to the respiratory tract, but they also invade the" exact="Central Nervous System" post="(CNS) to induce neurological diseases. Coronaviruses with such potential"/>
 <result pre="to the respiratory tract, but they also invade the Central" exact="Nervous System" post="(CNS) to induce neurological diseases. Coronaviruses with such potential"/>
 <result pre="(Talbot et al., 1994), HCoV-OC43 (Dubé et al., 2018), mouse" exact="hepatitis" post="virus (MHV) (Zhou et al., 2017), and Porcine Hemagglutinating"/>
 <result pre="al., 1972). According to previous study, coronaviruses may initially invade" exact="peripheral" post="nerves and enter the CNS via the synaptic route,"/>
 <result pre="this trans-synaptic transfer has been documented in HEV67 and avian" exact="bronchitis" post="virus (Matsuda et al., 2004). The first coronavirus found"/>
 <result pre="is enough for the virus to enter and destroy the" exact="medullary" post="neurons. A possible mechanism about the entry of SARS-CoV-2"/>
 <result pre="). Similarly, Matthew, 2020stated that the symptoms might attribute to" exact="respiratory" post="disease is due to the inability of air to"/>
 <result pre="Similarly, Matthew, 2020stated that the symptoms might attribute to respiratory" exact="disease" post="is due to the inability of air to get"/>
 <result pre="vomiting (1%). As the neuroinvasion of SARS-CoV-2 is accompanied by" exact="respiratory" post="failure in COVID-19 patients, the entry of the virus"/>
 <result pre="important to find effective antiviral drugs that can cross the" exact="blood-brain barrier" post="(Li et al., 2020). Therefore, more innovative approaches are"/>
 <result pre="2020). Therefore, more innovative approaches are required to detect this" exact="viral infection" post="at an earlier period. Fig. 3 COVID-19 entry into"/>
 <result pre="Therefore, more innovative approaches are required to detect this viral" exact="infection" post="at an earlier period. Fig. 3 COVID-19 entry into"/>
 <result pre="of human Coronavirus in CNS through olfactory bulb upon nasal" exact="infection" post="which causes inflammation and demyelination. Further it reaches the"/>
 <result pre="inflammation and demyelination. Further it reaches the whole brain via" exact="Blood" post="Brain Barrier and CSF via Blood- CSF barrier in"/>
 <result pre="and demyelination. Further it reaches the whole brain via Blood" exact="Brain" post="Barrier and CSF via Blood- CSF barrier in &amp;lt;7"/>
 <result pre="in &amp;lt;7 days. The possible entry of SARS-CoV-2 into the" exact="Brain" post="and CNS is important to design effective antiviral drugs."/>
 <result pre="to design effective antiviral drugs. Effective drugs that may cross" exact="Blood" post="Brain Barrier and Blood CSF barrier may be taken"/>
 <result pre="design effective antiviral drugs. Effective drugs that may cross Blood" exact="Brain" post="Barrier and Blood CSF barrier may be taken in"/>
 <result pre="drugs. Effective drugs that may cross Blood Brain Barrier and" exact="Blood" post="CSF barrier may be taken in to consideration while"/>
 <result pre="is now essential to develop specific tests for COVID-19. The" exact="viral" post="nucleic acid detection is primarily used in SARS-CoV-2 diagnosis"/>
 <result pre="Wang et al., 2020c). CDC has recommended the collection of" exact="upper" post="respiratory nasopharyngeal (NP) swabs for the diagnostic tests (CDC,"/>
 <result pre="et al., 2020c). CDC has recommended the collection of upper" exact="respiratory" post="nasopharyngeal (NP) swabs for the diagnostic tests (CDC, 2020)."/>
 <result pre="also be utilized as a diagnostic method in COVID-19. Additionally," exact="chest" post="CT scans have been facilitated to detect lung abnormalities"/>
 <result pre="have been facilitated to detect lung abnormalities in this SARS-CoV-2" exact="infection" post="(Shi et al., 2020; Xu et al., 2020a, Xu"/>
 <result pre="2020b). Abnormalities in the CT scans can be concomitant with" exact="disease" post="progression and prognosis. But, not all the cases can"/>
 <result pre="drugs mostly target the four major groups of viruses: human" exact="immunodeficiency" post="virus (HIV), herpes, hepatitis and influenza (Razonable, 2011). Earlier"/>
 <result pre="four major groups of viruses: human immunodeficiency virus (HIV), herpes," exact="hepatitis" post="and influenza (Razonable, 2011). Earlier outbreak episodes of viral"/>
 <result pre="herpes, hepatitis and influenza (Razonable, 2011). Earlier outbreak episodes of" exact="viral" post="infections like SARS-CoV and MERS-CoV as well as hemorrhagic"/>
 <result pre="hepatitis and influenza (Razonable, 2011). Earlier outbreak episodes of viral" exact="infections" post="like SARS-CoV and MERS-CoV as well as hemorrhagic fever"/>
 <result pre="observed in COVID-19. Anti-inflammatory drugs especially JAK-STAT inhibitors, used against" exact="rheumatoid arthritis," post="may be effective against elevated levels of cytokines and"/>
 <result pre="effective against elevated levels of cytokines and useful in inhibiting" exact="viral infection." post="According to recent study, an inflammatory drug, baricitinib when"/>
 <result pre="like Remidesivir, increases the potential of the drug to reduce" exact="viral infection" post="(Stebbing et al., 2020). 9.5 Monoclonal antibodies The virus"/>
 <result pre="Remidesivir, increases the potential of the drug to reduce viral" exact="infection" post="(Stebbing et al., 2020). 9.5 Monoclonal antibodies The virus"/>
 <result pre="is a high possibility for reducing the severity of the" exact="disease" post="(Zheng and Song, 2020). Currently, only a handful of"/>
 <result pre="a pandemic by WHO, there was an immense lack of" exact="disease" post="specific drugs. Being a rapidly spreading virus, it is"/>
 <result pre="Name of drug Illnesses treated References 1. α-Interferon Spectrum of" exact="respiratory" post="infections, RSV and SARS (Cinatl et al., 2003; Guerrero"/>
 <result pre="MERS (Chu et al., 2004) 3. Ribavirin RSV and RSV" exact="pneumonia" post="(Lewinsohn et al., 1996; McIntosh et al., 1984) 4."/>
 <result pre="De Clercq, 2007 9. Umifenovir ARVI, influenza, rhinovirus, adenovirus, parainfluenza," exact="respiratory" post="syncytial virus, coronavirus, including the causative agent of atypical"/>
 <result pre="parainfluenza, respiratory syncytial virus, coronavirus, including the causative agent of" exact="atypical" post="pneumoniaUsed in the phase III trials of 2019- nCoV"/>
 <result pre="et al., 2004; Vincent et al., 2005) 23. ASC09 ARDS," exact="Respiratory" post="distress syndrome, SARS, MERS (March and Bogatcheva, 2018, March"/>
 <result pre="for the treatment of the various forms of coronaviruses. The" exact="viral" post="infections discussed in the table are SARS - Severe"/>
 <result pre="the treatment of the various forms of coronaviruses. The viral" exact="infections" post="discussed in the table are SARS - Severe Acute"/>
 <result pre="The viral infections discussed in the table are SARS -" exact="Severe" post="Acute Respiratory Syndrome, MERS - Middle East Respiratory Syndrome,"/>
 <result pre="viral infections discussed in the table are SARS - Severe" exact="Acute" post="Respiratory Syndrome, MERS - Middle East Respiratory Syndrome, RSV"/>
 <result pre="infections discussed in the table are SARS - Severe Acute" exact="Respiratory" post="Syndrome, MERS - Middle East Respiratory Syndrome, RSV -"/>
 <result pre="SARS - Severe Acute Respiratory Syndrome, MERS - Middle East" exact="Respiratory" post="Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute"/>
 <result pre="Respiratory Syndrome, MERS - Middle East Respiratory Syndrome, RSV -" exact="Respiratory" post="Syncytial Virus, ARVI - Acute respiratory viral infections. 10.1"/>
 <result pre="East Respiratory Syndrome, RSV - Respiratory Syncytial Virus, ARVI -" exact="Acute" post="respiratory viral infections. 10.1 Ribavirin Ribavirin is also a"/>
 <result pre="Respiratory Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute" exact="respiratory" post="viral infections. 10.1 Ribavirin Ribavirin is also a broad-spectrum"/>
 <result pre="Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute respiratory" exact="viral" post="infections. 10.1 Ribavirin Ribavirin is also a broad-spectrum drug"/>
 <result pre="1972. This antiviral drug is used in the treatment of" exact="hepatitis" post="C. It is usually used in combination with interferon"/>
 <result pre="as a nucleotide polymerase inhibitor used for the treatment of" exact="hepatitis" post="C. It was used in combination with interferon or"/>
 <result pre="the FDA by 2000. This drug prevents the formation of" exact="viral" post="proteins by disrupting the proteolytic processing by mimicking its"/>
 <result pre="with another flu drug oseltamivir was reported to result in" exact="complete" post="recovery after showing signs of COVID-19 related pneumonia (Wu"/>
 <result pre="result in complete recovery after showing signs of COVID-19 related" exact="pneumonia" post="(Wu et al., 2020a, Wu et al., 2020b). 10.4"/>
 <result pre="potential drug which causes premature termination by entering the nascent" exact="viral" post="RNA (Warren et al., 2016). Currently, it is undergoing"/>
 <result pre="0.77 μM at half maximal concentration against COVID-19 and blocked" exact="viral infection" post="(Wang et al., 2020a, Wang et al., 2020b, Wang"/>
 <result pre="μM at half maximal concentration against COVID-19 and blocked viral" exact="infection" post="(Wang et al., 2020a, Wang et al., 2020b, Wang"/>
 <result pre="an anti-malarial drug, has shown potential in the treatment of" exact="avian influenza" post="A (Yan et al., 2013). Chloroquine also has shown"/>
 <result pre="1.13 μM at half maximal concentration against SARS-CoV-2 and blocked" exact="viral infection" post="by increasing the endosomal pH required for viral fusion"/>
 <result pre="μM at half maximal concentration against SARS-CoV-2 and blocked viral" exact="infection" post="by increasing the endosomal pH required for viral fusion"/>
 <result pre="blocked viral infection by increasing the endosomal pH required for" exact="viral" post="fusion (Wang et al., 2020a, Wang et al., 2020b,"/>
 <result pre="such as National Institutes of Health (NIH), USA to identify" exact="disease" post="specific drugs. The major drugs undergoing clinical trials that"/>
 <result pre="undergoing clinical trials that have the potential to treat this" exact="viral infection" post="(Table 3 ). More research may be required in"/>
 <result pre="clinical trials that have the potential to treat this viral" exact="infection" post="(Table 3 ). More research may be required in"/>
 <result pre="Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With" exact="Severe" post="Coronavirus Disease (COVID-19) Remdesivir Recruiting 1. Hoag Memorial Hospital"/>
 <result pre="Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus" exact="Disease" post="(COVID-19) Remdesivir Recruiting 1. Hoag Memorial Hospital PresbyterianNewport Beach,"/>
 <result pre="Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus" exact="Disease" post="(COVID-19) Compared to Standard of Care Treatment Remdesivir Recruiting"/>
 <result pre="of Health - Clinical Center, National Institute of Allergy and" exact="Infectious" post="Diseases Laboratory Of Immunoregulation, Clinical Research SectionBethesda, Maryland, United"/>
 <result pre="Health - Clinical Center, National Institute of Allergy and Infectious" exact="Diseases" post="Laboratory Of Immunoregulation, Clinical Research SectionBethesda, Maryland, United States2."/>
 <result pre="SectionBethesda, Maryland, United States2. University of Nebraska Medical Center -" exact="Infectious" post="DiseasesOmaha, Nebraska, United States3. University of Texas Medical Branch"/>
 <result pre="United States3. University of Texas Medical Branch - Division of" exact="Infectious" post="DiseaseGalveston, Texas, United States4. Providence Sacred Heart Medical CenterSpokane,"/>
 <result pre="- Division of Infectious DiseaseGalveston, Texas, United States4. Providence Sacred" exact="Heart" post="Medical CenterSpokane, Washington, United States 9. Severe 2019-nCoV Remdesivir"/>
 <result pre="States4. Providence Sacred Heart Medical CenterSpokane, Washington, United States 9." exact="Severe" post="2019-nCoV Remdesivir RCT Remdesivir Recruiting Bin CaoBeijing, Beijing, China"/>
 <result pre="Bin CaoBeijing, Beijing, China 10. Nitric Oxide Gas Inhalation for" exact="Severe" post="Acute Respiratory Syndrome in COVID-19. Nitric Oxide Gas Not"/>
 <result pre="CaoBeijing, Beijing, China 10. Nitric Oxide Gas Inhalation for Severe" exact="Acute" post="Respiratory Syndrome in COVID-19. Nitric Oxide Gas Not yet"/>
 <result pre="Beijing, China 10. Nitric Oxide Gas Inhalation for Severe Acute" exact="Respiratory" post="Syndrome in COVID-19. Nitric Oxide Gas Not yet recruiting"/>
 <result pre="China 10. Nitric Oxide Gas Inhalation for Severe Acute Respiratory" exact="Syndrome" post="in COVID-19. Nitric Oxide Gas Not yet recruiting –"/>
 <result pre="Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus" exact="Infection" post="1.ASC09/ritonavir group2. Lopinavir/ritonavir group Not yet recruiting – 13."/>
 <result pre="and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2" exact="Infection" post="mRNA-1273 Not yet recruiting Kaiser Permanente Washington Health Research"/>
 <result pre="recruiting Kaiser Permanente Washington Health Research Institute - Vaccines and" exact="Infectious" post="DiseasesSeattle, Washington, United States 14. Glucocorticoid Therapy for Novel"/>
 <result pre="States 14. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With" exact="Severe" post="Acute Respiratory Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical"/>
 <result pre="14. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe" exact="Acute" post="Respiratory Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical College"/>
 <result pre="Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute" exact="Respiratory" post="Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical College HospitalBeijing,"/>
 <result pre="Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory" exact="Failure" post="Methylprednisolone Recruiting Medical ICU,Peking Union Medical College HospitalBeijing, Beijing,"/>
 <result pre="for the efficacy of hydroxychloroquine for mild and moderate COVID-19" exact="infectious diseases" post="Hydroxychloroquine – The Second Affiliated Hospital of Chongqing Medical"/>
 <result pre="and safety of carrimycin treatment in patients with novel coronavirus" exact="infectious disease" post="(COVID-19): a multicenter, randomized, open- label controlled trial Carrimycin"/>
 <result pre="safety of carrimycin treatment in patients with novel coronavirus infectious" exact="disease" post="(COVID-19): a multicenter, randomized, open- label controlled trial Carrimycin"/>
 <result pre="alpha 1b spray in the prevention of novel coronavirus (COVID-19)" exact="infection" post="in highly exposed medical staffs. recombinant human interferon alpha"/>
 <result pre="medical staffs. recombinant human interferon alpha 1b – Chinese PLA" exact="General" post="Hospital 21. A Pilot Study of Sildenafil in COVID-19"/>
 <result pre="Sildenafil in COVID-19 Sildenafil citrate Recruiting Department and Institute of" exact="Infectious" post="Disease, Wuhan, Hubei, China 22. Comparison of Lopinavir/Ritonavir or"/>
 <result pre="Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus" exact="Disease" post="(COVID-19) 1.Lopinavir/ritonavir 2.Hydroxychloroquine sulfate Recruiting Asan Medical Center, University"/>
 <result pre="Republic of Korea 23. The Efficacy and Safety of Thalidomide" exact="Combined" post="With Low-dose Hormones in the Treatment of Severe COVID-19"/>
 <result pre="of Thalidomide Combined With Low-dose Hormones in the Treatment of" exact="Severe" post="COVID-19 Thalidomide Not yet recruiting – 24. Various Combination"/>
 <result pre="recruiting Subsai Kongsaengdao, Bangkok, Thailand 25. Chloroquine Prevention of Coronavirus" exact="Disease" post="(COVID-19) in the Healthcare Setting Chloroquine Not yet recruiting"/>
 <result pre="the Healthcare Setting Chloroquine Not yet recruiting – 26. Favipiravir" exact="Combined" post="With Tocilizumab in the Treatment of Corona Virus Disease"/>
 <result pre="26. Favipiravir Combined With Tocilizumab in the Treatment of Corona" exact="Virus Disease" post="2019 Favipiravir Combined with Tocilizumab Recruiting Anhui Medical University"/>
 <result pre="Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus" exact="Disease" post="2019 Favipiravir Combined with Tocilizumab Recruiting Anhui Medical University"/>
 <result pre="Tocilizumab in the Treatment of Corona Virus Disease 2019 Favipiravir" exact="Combined" post="with Tocilizumab Recruiting Anhui Medical University Affiliated First Hospital,"/>
 <result pre="Minnesota, Minneapolis, Minnesota, United States 30. Evaluation of Ganovo (Danoprevir)" exact="Combined" post="With Ritonavir in the Treatment of Novel Coronavirus Infection"/>
 <result pre="(Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus" exact="Infection" post="Ganovo with ritonavir +/-Interferon Recruiting The Ninth Hospital of"/>
 <result pre="Access Remdesivir (RDV; GS-5734™) Remdesivir Initiated – 33. Norwegian Coronavirus" exact="Disease" post="2019 Study Hydroxychloroquine Sulfate Not yet recruiting – 34."/>
 <result pre="safety of pirfenidone capsules in the treatment of severe new" exact="coronavirus pneumonia" post="(COVID-19) Pirfenidone – Third Xiangya Hospital of Central South"/>
 <result pre="of pirfenidone capsules in the treatment of severe new coronavirus" exact="pneumonia" post="(COVID-19) Pirfenidone – Third Xiangya Hospital of Central South"/>
 <result pre="new coronavirus pneumonia (COVID-19) Pirfenidone – Third Xiangya Hospital of" exact="Central" post="South University The table represents a list of selected"/>
 <result pre="remedies in Indian medicine (Pundarikakshudu and Kanaki, 2019). Recently, the" exact="total" post="number of Indian medicinal plants was estimated to be"/>
 <result pre="compounds with antiviral activity has often been unsatisfactory due to" exact="viral" post="resistance along with viral latency and recurrent infection in"/>
 <result pre="has often been unsatisfactory due to viral resistance along with" exact="viral" post="latency and recurrent infection in immune-compromised patients (Sumithira et"/>
 <result pre="unsatisfactory due to viral resistance along with viral latency and" exact="recurrent" post="infection in immune-compromised patients (Sumithira et al., 2012). Among"/>
 <result pre="due to viral resistance along with viral latency and recurrent" exact="infection" post="in immune-compromised patients (Sumithira et al., 2012). Among antiviral"/>
 <result pre="plants have played a tremendous role at different stages of" exact="viral" post="growth (Akram et al., 2018). Plant derived pharmacological formulations"/>
 <result pre="2018). Plant derived pharmacological formulations marked a major contribution for" exact="viral" post="infections (Cragg et al., 1997). Based on the availability"/>
 <result pre="Plant derived pharmacological formulations marked a major contribution for viral" exact="infections" post="(Cragg et al., 1997). Based on the availability of"/>
 <result pre="by medicinal plants, as life-saving drugs (Gurib-Fakim, 2006) in various" exact="viral" post="diseases. Unfortunately, the usage of these medication have been"/>
 <result pre="as a treatment and preventive strategy for several diseases, including" exact="respiratory" post="viral infections. The benefit of using these herbs in"/>
 <result pre="a treatment and preventive strategy for several diseases, including respiratory" exact="viral" post="infections. The benefit of using these herbs in viral"/>
 <result pre="respiratory viral infections. The benefit of using these herbs in" exact="viral" post="respiratory infections is to build immune stimulating and inflammation"/>
 <result pre="viral infections. The benefit of using these herbs in viral" exact="respiratory" post="infections is to build immune stimulating and inflammation modulating"/>
 <result pre="infections. The benefit of using these herbs in viral respiratory" exact="infections" post="is to build immune stimulating and inflammation modulating effects"/>
 <result pre="the NF-kB pathway, a pathway that has been implicated in" exact="respiratory" post="distress in SARS-CoV (Alam et al., 2002; Srivastava et"/>
 <result pre="(Keyaerts et al., 2007) have been known to target the" exact="viral" post="replication of SARS-CoV, arising as promising candidates against SARS-CoV-2."/>
 <result pre="has been found to have the potential to inactivate the" exact="viral" post="ribosome, this can be further investigated for its utility"/>
 <result pre="1996). Similarly, Strobilanthes Cusia (Tsai et al., 2020) blocked the" exact="viral" post="RNA genome synthesis and induced papain like protease activity"/>
 <result pre="a study has documented the presence of ethnomedicinal plants against" exact="bronchitis" post="(Amber et al., 2017). The study screened the antiviral"/>
 <result pre="showed that Hyoscyamus niger, Justicia adhatoda and Verbascum thapsus reduced" exact="infections" post="caused by influenza viruses. The molecular mechanism by which"/>
 <result pre="target the orf3a Ca2+channels that trigger various downstream pathways upon" exact="viral infection." post="Most importantly, various medicinal plants have shown inhibitory effects"/>
 <result pre="present in South Asia has a strong treating capacity of" exact="viral" post="respiratory infections in Ayurvedic and other medicinal systems (Yarnell,"/>
 <result pre="in South Asia has a strong treating capacity of viral" exact="respiratory" post="infections in Ayurvedic and other medicinal systems (Yarnell, 2018;"/>
 <result pre="South Asia has a strong treating capacity of viral respiratory" exact="infections" post="in Ayurvedic and other medicinal systems (Yarnell, 2018; Arora"/>
 <result pre="Various Indian medicinal plants that have been widely used for" exact="respiratory" post="diseases have been included (Supplementary Table 1). 13 COVID-19"/>
 <result pre="This is attributed to the fact that COVID-19 is a" exact="viral infection" post="that has been known to have the fastest frequency"/>
 <result pre="is attributed to the fact that COVID-19 is a viral" exact="infection" post="that has been known to have the fastest frequency"/>
 <result pre="positive strand resulting in the quick formation of new progeny" exact="viral" post="cells inside the host cells. It has also been"/>
 <result pre="which has created a barrier for both investigations of the" exact="disease" post="and therapeutic regimens (American Society for Microbiology, 2020). Recently,"/>
 <result pre="host cell, which has resulted in the escalation of the" exact="infection" post="in limited time. Hence, it has become a big"/>
 <result pre="which has resulted in the escalation of the infection in" exact="limited" post="time. Hence, it has become a big challenge to"/>
 <result pre="challenge to analyze the condition and offer therapy at the" exact="short" post="time available. Due to the high mutation rate, it"/>
 <result pre="g with warm water Twice a day for 15 days" exact="Chronic" post="fever Andrograhis paniculata Aqueous Nilavembu kudineer Siddha Nilavembu kudineer"/>
 <result pre="kudineer 60 ml decoction Twice a day for 14 days" exact="Fever" post="and cold Cydonia oblongaZizyphus jujubeCordia myxa Aqueous BehidanaUnnabSapistan Unani"/>
 <result pre="Twice a day for 14 days Antioxidant, immune-modulatory, anti-allergic, smooth" exact="muscle" post="relaxant, anti-influenza activity Arsenicum album 30 Tablet Arsenicum album"/>
 <result pre="3 days (Should be repeated after 1 month till the" exact="infection" post="persist). Effective against SARS-CoV-2, immune-modulator.    Symptomatic Management for"/>
 <result pre="-64 Tablet – Ayurveda – 2 tablets twice a day" exact="Respiratory" post="infections Agastya Haritaki Powder Agasthya Rasayanam Ayurveda 5 g"/>
 <result pre="Tablet – Ayurveda – 2 tablets twice a day Respiratory" exact="infections" post="Agastya Haritaki Powder Agasthya Rasayanam Ayurveda 5 g in"/>
 <result pre="Ayurveda 5 g in warm water Twice a day Upper" exact="respiratory" post="infections Anuthaila Oil Sesame oil Ayurveda – 2 drops"/>
 <result pre="5 g in warm water Twice a day Upper respiratory" exact="infections" post="Anuthaila Oil Sesame oil Ayurveda – 2 drops in"/>
 <result pre="oil Ayurveda – 2 drops in each nostril daily morning" exact="Respiratory" post="infections Adathodai Manapagu Aqueous Adathodai Manapagu Siddha – 10"/>
 <result pre="Ayurveda – 2 drops in each nostril daily morning Respiratory" exact="infections" post="Adathodai Manapagu Aqueous Adathodai Manapagu Siddha – 10 ml"/>
 <result pre="Aqueous Adathodai Manapagu Siddha – 10 ml twice a day" exact="Fever" post="Bryonia alba Tablet Bryonia Homeopathy – – Reduce lung"/>
 <result pre="day Fever Bryonia alba Tablet Bryonia Homeopathy – – Reduce" exact="lung inflammation" post="Rhus toxico dendron Tablet Rhus tox Homeopathy – –"/>
 <result pre="inflammation Rhus toxico dendron Tablet Rhus tox Homeopathy – –" exact="Viral" post="infections Atropa belladonna Tablet Belladonna Homeopathy – – Asthma"/>
 <result pre="Rhus toxico dendron Tablet Rhus tox Homeopathy – – Viral" exact="infections" post="Atropa belladonna Tablet Belladonna Homeopathy – – Asthma and"/>
 <result pre="– Viral infections Atropa belladonna Tablet Belladonna Homeopathy – –" exact="Asthma" post="and chronic lung diseases Bignonia sempervirens Tablet Gelsemium Homeopathy"/>
 <result pre="infections Atropa belladonna Tablet Belladonna Homeopathy – – Asthma and" exact="chronic" post="lung diseases Bignonia sempervirens Tablet Gelsemium Homeopathy – –"/>
 <result pre="Atropa belladonna Tablet Belladonna Homeopathy – – Asthma and chronic" exact="lung diseases" post="Bignonia sempervirens Tablet Gelsemium Homeopathy – – Asthma Eupatorium"/>
 <result pre="chronic lung diseases Bignonia sempervirens Tablet Gelsemium Homeopathy – –" exact="Asthma" post="Eupatorium perfoliatum Tablet Eupatorium perfoliatum Homeopathy – – Respiratory"/>
 <result pre="– Asthma Eupatorium perfoliatum Tablet Eupatorium perfoliatum Homeopathy – –" exact="Respiratory" post="symptoms    Add on interventions to the conventional care"/>
 <result pre="Tablet Poly-herbal formulation Siddha Decoction 60 ml Twice a day" exact="Fever" post="Kaba sura kudineer Tablet Poly-herbal formulation Siddha Decoction 60"/>
 <result pre="al., 2014 2. Allium sativum Proteolytic and hemagglutinating activity and" exact="viral" post="replication – SARS Keyaerts et al., 2004 3. Andrographis"/>
 <result pre="PR Mishra et al., 2014 12. Glycyrrhiza glabra Inhibition of" exact="viral" post="replication; Modulation of membrane fluidity SARS; HIV-1 Akamatsu et"/>
 <result pre="2003; Fiore et al., 2008 13. Gymnema sylvestre Inhibition of" exact="viral" post="DNA synthesis – – Vimalanathan et al., 2009; Arun"/>
 <result pre="– – HIV-1 Yu, 2004 21. Sphaeranthus indicus Inhibition –" exact="Mouse" post="corona virus and Herpes virus Galani et al., 2010Tiwari"/>
 <result pre="al., 2018 HIV-1PR: Human Influenza Virus – 1 Protease; SARS:" exact="Severe" post="Acute Respiratory Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome –"/>
 <result pre="2018 HIV-1PR: Human Influenza Virus – 1 Protease; SARS: Severe" exact="Acute" post="Respiratory Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome – Coranavirus;"/>
 <result pre="HIV-1PR: Human Influenza Virus – 1 Protease; SARS: Severe Acute" exact="Respiratory" post="Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome – Coranavirus; SARS-CoV-2:"/>
 <result pre="Virus – 1 Protease; SARS: Severe Acute Respiratory Syndrome; SARS-CoV:" exact="Severe" post="Acute Respiratory Syndrome – Coranavirus; SARS-CoV-2: Severe Acute Respiratory"/>
 <result pre="– 1 Protease; SARS: Severe Acute Respiratory Syndrome; SARS-CoV: Severe" exact="Acute" post="Respiratory Syndrome – Coranavirus; SARS-CoV-2: Severe Acute Respiratory Syndrome"/>
 <result pre="1 Protease; SARS: Severe Acute Respiratory Syndrome; SARS-CoV: Severe Acute" exact="Respiratory" post="Syndrome – Coranavirus; SARS-CoV-2: Severe Acute Respiratory Syndrome –"/>
 <result pre="Protease; SARS: Severe Acute Respiratory Syndrome; SARS-CoV: Severe Acute Respiratory" exact="Syndrome" post="– Coranavirus; SARS-CoV-2: Severe Acute Respiratory Syndrome – Coranavirus"/>
 <result pre="Respiratory Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome – Coranavirus; SARS-CoV-2:" exact="Severe" post="Acute Respiratory Syndrome – Coranavirus 2; ACE – Angiotensin"/>
 <result pre="Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome – Coranavirus; SARS-CoV-2: Severe" exact="Acute" post="Respiratory Syndrome – Coranavirus 2; ACE – Angiotensin converting"/>
 <result pre="SARS-CoV: Severe Acute Respiratory Syndrome – Coranavirus; SARS-CoV-2: Severe Acute" exact="Respiratory" post="Syndrome – Coranavirus 2; ACE – Angiotensin converting enzyme;"/>
 <result pre="Severe Acute Respiratory Syndrome – Coranavirus; SARS-CoV-2: Severe Acute Respiratory" exact="Syndrome" post="– Coranavirus 2; ACE – Angiotensin converting enzyme; HIV-1:"/>
 <result pre="of Differentiation; HCoV-NL63: Human coronavirus NL63; RNA: Ribonucleic acid; MHV-A59:" exact="Mouse" post="Hepatitis Virus –A59; CA2+: Calcium ion; NLRP3: NLR Family"/>
 <result pre="Differentiation; HCoV-NL63: Human coronavirus NL63; RNA: Ribonucleic acid; MHV-A59: Mouse" exact="Hepatitis" post="Virus –A59; CA2+: Calcium ion; NLRP3: NLR Family Pyrin"/>
 <result pre="hard to predict. The health care professionals and equipment are" exact="limited" post="and are unable to handle the vast number of"/>
 <result pre="who are infected. Moreover, some of the individuals who are" exact="infectious" post="are asymptomatic and continue to travel or gather in"/>
 <result pre="there was an urge to discover the root cause of" exact="coronavirus infections" post="not only in animals but in humans as well."/>
 <result pre="was an urge to discover the root cause of coronavirus" exact="infections" post="not only in animals but in humans as well."/>
 <result pre="Currently, COVID-19 has emerged as the most intense and petrifying" exact="viral infection" post="to be handled by the human race. According to"/>
 <result pre="COVID-19 has emerged as the most intense and petrifying viral" exact="infection" post="to be handled by the human race. According to"/>
 <result pre="influx of new COVID-19 cases in a given time period." exact="Total" post="confirmed cases throughout the world are 4,16,686 and total"/>
 <result pre="period. Total confirmed cases throughout the world are 4,16,686 and" exact="total" post="number of confirmed deaths are 18,589 (WHO, 2020a) as"/>
 <result pre="identified in the coming days in India. This increase in" exact="infection" post="was mainly due to the ability of this virus"/>
 <result pre="been used for several decades in the treatment of various" exact="respiratory" post="conditions. It highlights the pathways that the plant-based medicines"/>
 <result pre="pathways that the plant-based medicines may target to reduce the" exact="disease" post="burden. Thus, proactive investments in researches based on Indian"/>
 <result pre="associated with COVID-19 ranges from difficulties in breathing and other" exact="respiratory" post="conditions to critical conditions including SARS, kidney failure and"/>
 <result pre="breathing and other respiratory conditions to critical conditions including SARS," exact="kidney failure" post="and sometimes even death. Individuals are likely to be"/>
 <result pre="by others who have been inflicted with the virus. The" exact="disease" post="can spread from person to person via small droplets"/>
 <result pre="older persons and persons with pre-existing medical conditions (such as" exact="high blood pressure," post="heart disease, lung disease, cancer or diabetes) appear to"/>
 <result pre="persons with pre-existing medical conditions (such as high blood pressure," exact="heart" post="disease, lung disease, cancer or diabetes) appear to develop"/>
 <result pre="pre-existing medical conditions (such as high blood pressure, heart disease," exact="lung disease," post="cancer or diabetes) appear to develop serious illness more"/>
 <result pre="conditions (such as high blood pressure, heart disease, lung disease," exact="cancer" post="or diabetes) appear to develop serious illness more often"/>
 <result pre="illness more often than others, also pregnant women with the" exact="infection" post="had did not pass the infection to their unborn"/>
 <result pre="pregnant women with the infection had did not pass the" exact="infection" post="to their unborn babies (Wu and McGoogan, 2020; Chen"/>
 <result pre="the Asian populations are more susceptible to acquire this COVID-19" exact="infection" post="when compared to the other races populations (Xu, 2020)."/>
 <result pre="1 List of commonly used Indian medicinal plants involved in" exact="respiratory" post="diseases. LINK Supplementary Table 1 Authors contribution Conceptualization: BV;"/>
 <result pre="and Engineering Research Board (SERB), Government of India [ECR/2018/000718]; The" exact="Advanced" post="Level State Biotech Hub (BT/04/NE/2009 Dt.29.082014), India; the Expanding"/>
 <result pre="influence the work reported in this paper. References References AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.RayA.S.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleaseMBio.922018e00221-1810.1128/mBio.00221-18 AkamatsuH.KomuraJ.AsadaY.NiwaY.Mechanism of anti-inflammatory action"/>
 <result pre="activity of the Himalayan medicinal plants traditionally used to treat" exact="bronchitis" post="and related symptomsJ. Pharm. Pharmacol.69201710912210.1111/jphp.1266927905101 American Society of Microbiologyhttps://asm.org/PressReleases/2020/COVID-19-Resources2020"/>
 <result pre="traditionally used to treat bronchitis and related symptomsJ. Pharm. Pharmacol.69201710912210.1111/jphp.1266927905101" exact="American" post="Society of Microbiologyhttps://asm.org/PressReleases/2020/COVID-19-Resources2020 AngelettiS.BenvenutoD.BianchiM.GiovanettiM.PascarellaS.CiccozziM.COVID-2019: the role of the nsp2"/>
 <result pre="229E for cathepsin-independent host cell entry and is expressed in" exact="viral" post="target cells in the respiratory epitheliumJ. Virol.8720136150616010.1128/JVI.03372-1223536651 BlanchardJ.E.EloweN.H.HuitemaC.FortinP.D.CechettoJ.D.EltisL.D.BrownE.D.High-throughput screening"/>
 <result pre="entry and is expressed in viral target cells in the" exact="respiratory" post="epitheliumJ. Virol.8720136150616010.1128/JVI.03372-1223536651 BlanchardJ.E.EloweN.H.HuitemaC.FortinP.D.CechettoJ.D.EltisL.D.BrownE.D.High-throughput screening identifies inhibitors of the SARS"/>
 <result pre="BunteK.BeiklerT.Th17 cells and the IL-23/IL-17 axis in the pathogenesis of" exact="periodontitis" post="and immune-mediated inflammatory diseasesInt. J. Mol. Sci.202019339410.3390/ijms20143394 CaoY.Suggestion Using"/>
 <result pre="Sci.202019339410.3390/ijms20143394 CaoY.Suggestion Using Alcohol Vaporization or Nebulization Inhalation Therapy for" exact="Pneumonitis" post="Caused by Coronavirus2020(Available at SSRN 3545744) CecereT.E.ToddS.M.LeRoithT.Regulatory T cells"/>
 <result pre="cells in arterivirus and coronavirus infections: do they protect against" exact="disease" post="or enhance it?Viruses4201283384610.3390/v405083322754651 Centers for Disease Prevention and Control"/>
 <result pre="do they protect against disease or enhance it?Viruses4201283384610.3390/v405083322754651 Centers for" exact="Disease" post="Prevention and Control (CDC)https://www.cdc.gov/coronavirus/2019-ncov/index.html2020(Accessed on 25 March 2020) ChanJ.F.W.KokK.H.ZhuZ.ChuH.ToK.K.W.YuanS.YuenK.Y.Genomic"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical" post="pneumonia after visiting WuhanEmerg. Microbes Infect.9202022123631987001 ChanJ.F.W.YipC.C.Y.ToK.K.W.TangT.H.C.WongS.C.Y.LeungK.H.FungA.Y.F.NgA.C.K.ZouZ.TsoiH.W.Improved molecular diagnosis"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microbes Infect.9202022123631987001 ChanJ.F.W.YipC.C.Y.ToK.K.W.TangT.H.C.WongS.C.Y.LeungK.H.FungA.Y.F.NgA.C.K.ZouZ.TsoiH.W.Improved molecular diagnosis of"/>
 <result pre="CheemaS.U.R.RehmanM.S.HussainG.CheemaS.S.GilaniN.Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of" exact="hepatitis" post="C genotype 1 &amp;amp; 3 in patients undergoing hemodialysis-a"/>
 <result pre="with other emerging virusesMicrobes Infect.222020697110.1016/j.micinf.2020.01.00432032682 ChenJ.LauY.F.LamirandeE.W.PaddockC.D.BartlettJ.H.ZakiS.R.SubbaraoK.Cellular immune responses to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice:"/>
 <result pre="other emerging virusesMicrobes Infect.222020697110.1016/j.micinf.2020.01.00432032682 ChenJ.LauY.F.LamirandeE.W.PaddockC.D.BartlettJ.H.ZakiS.R.SubbaraoK.Cellular immune responses to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+"/>
 <result pre="emerging virusesMicrobes Infect.222020697110.1016/j.micinf.2020.01.00432032682 ChenJ.LauY.F.LamirandeE.W.PaddockC.D.BartlettJ.H.ZakiS.R.SubbaraoK.Cellular immune responses to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T"/>
 <result pre="ChenJ.LauY.F.LamirandeE.W.PaddockC.D.BartlettJ.H.ZakiS.R.SubbaraoK.Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
 <result pre="Virol.8420101289130110.1128/JVI.01281-0919906920 ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.LiJ.ZhaoD.XuD.GongQ.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
 <result pre="of medical recordsLancet395202080981510.1016/S0140-6736(20)30360-332151335 ChouC.Y.ChienC.H.HanY.S.PrebandaM.T.HsiehH.P.TurkB.ChangG.G.ChenX.Thiopurine analogues inhibit papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirusBiochem. Pharmacol.7520081601160910.1016/j.bcp.2008.01.00518313035 ChuC.ChengV.HungI.WongM.ChanK.H.ChanK.S.KaoR.PoonL.WongC.GuanY.Role of lopinavir/ritonavir in the"/>
 <result pre="medical recordsLancet395202080981510.1016/S0140-6736(20)30360-332151335 ChouC.Y.ChienC.H.HanY.S.PrebandaM.T.HsiehH.P.TurkB.ChangG.G.ChenX.Thiopurine analogues inhibit papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirusBiochem. Pharmacol.7520081601160910.1016/j.bcp.2008.01.00518313035 ChuC.ChengV.HungI.WongM.ChanK.H.ChanK.S.KaoR.PoonL.WongC.GuanY.Role of lopinavir/ritonavir in the treatment"/>
 <result pre="recordsLancet395202080981510.1016/S0140-6736(20)30360-332151335 ChouC.Y.ChienC.H.HanY.S.PrebandaM.T.HsiehH.P.TurkB.ChangG.G.ChenX.Thiopurine analogues inhibit papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirusBiochem. Pharmacol.7520081601160910.1016/j.bcp.2008.01.00518313035 ChuC.ChengV.HungI.WongM.ChanK.H.ChanK.S.KaoR.PoonL.WongC.GuanY.Role of lopinavir/ritonavir in the treatment of"/>
 <result pre="and renal passage and their use to treat or prevent" exact="infection" post="by coronaviruseshttps://europepmc.org/article/pat/wo20040938882005 ContiniA.Virtual screening of an FDA approved drugs"/>
 <result pre="COVID-19 coronavirus proteinsChem Rxiv202010.26434/chemrxiv.11847381.v1 CoonJ.T.ErnstE.Andrographis paniculata in the treatment of" exact="upper" post="respiratorytract infections: a systematic review of safety and efficacyPlanta"/>
 <result pre="and Functional Exhaustion of T Cells in Patients with Coronavirus" exact="Disease" post="2019 (COVID-19). medRxiv202010.1101/2020.02.18.20024364 DorigattiI.OkellL.CoriA.ImaiN.BaguelinM.BhatiaS.BoonyasiriA.CucunubáZ.Cuomo-DannenburgG.FitzJohnR.Report 4: Severity of 2019-Novel Coronavirus"/>
 <result pre="in Patients with Coronavirus Disease 2019 (COVID-19). medRxiv202010.1101/2020.02.18.20024364 DorigattiI.OkellL.CoriA.ImaiN.BaguelinM.BhatiaS.BoonyasiriA.CucunubáZ.Cuomo-DannenburgG.FitzJohnR.Report 4:" exact="Severity of" post="2019-Novel Coronavirus (nCoV)2020Imperial College10.25561/77154 DubéM.Le CoupanecA.WongA.H.RiniJ.M.DesforgesM.TalbotP.J.Axonal transport enables neuron-to-neuron"/>
 <result pre="Res.1201024725310.4103/0974-7788.7679021455454 GanjhuR.K.MudgalP.P.MaityH.DowarhaD.DevadigaS.NagS.ArunkumarG.Herbal plants and plant preparations as remedial approach for" exact="viral" post="diseasesVirusdisease26201522523610.1007/s13337-015-0276-626645032 GiererS.BertramS.KaupF.WrenschF.HeurichA.Krämer-KühlA.WelschK.WinklerM.MeyerB.DrostenC.The spike protein of the emerging betacoronavirus EMC"/>
 <result pre="Ca2+ channelsFundam. Clin. Pharmacol.222008879910.1111/j.1472-8206.2007.00561.x18251725 GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe" exact="acute" post="respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of miceJ. Immunol.17320044030403910.4049/jimmunol.173.6.403015356152 GomathiM.PadmapriyaS.BalachandarV.Drug"/>
 <result pre="channelsFundam. Clin. Pharmacol.222008879910.1111/j.1472-8206.2007.00561.x18251725 GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) pulmonary infection of miceJ. Immunol.17320044030403910.4049/jimmunol.173.6.403015356152 GomathiM.PadmapriyaS.BalachandarV.Drug studies"/>
 <result pre="GlassW.G.SubbaraoK.MurphyB.MurphyP.M.Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV)" exact="pulmonary" post="infection of miceJ. Immunol.17320044030403910.4049/jimmunol.173.6.403015356152 GomathiM.PadmapriyaS.BalachandarV.Drug studies on Rett syndrome:"/>
 <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of miceJ. Immunol.17320044030403910.4049/jimmunol.173.6.403015356152 GomathiM.PadmapriyaS.BalachandarV.Drug studies on Rett syndrome: from"/>
 <result pre="Immunol.17320044030403910.4049/jimmunol.173.6.403015356152 GomathiM.PadmapriyaS.BalachandarV.Drug studies on Rett syndrome: from bench to bedsideJ." exact="Autism" post="Dev. Disord.202012510.1007/s10803-020-04381-y31729599 GorbalenyaA.E.Severe acute respiratory syndrome-related coronavirus–the species and"/>
 <result pre="Rett syndrome: from bench to bedsideJ. Autism Dev. Disord.202012510.1007/s10803-020-04381-y31729599 GorbalenyaA.E.Severe" exact="acute" post="respiratory syndrome-related coronavirus–the species and its viruses, a statement"/>
 <result pre="syndrome: from bench to bedsideJ. Autism Dev. Disord.202012510.1007/s10803-020-04381-y31729599 GorbalenyaA.E.Severe acute" exact="respiratory" post="syndrome-related coronavirus–the species and its viruses, a statement of"/>
 <result pre="statement of the coronavirus study groupBioRxiv202010.1101/2020.02.07.937862 GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.L.LauberC.LeontovichA.M.NeumanB.W.PenzarD.PerlmanS.PoonL.L.M.SamborskiyD.V.SidorovI.A.SolaI.ZiebuhrJ.The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
 <result pre="of the coronavirus study groupBioRxiv202010.1101/2020.02.07.937862 GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.L.LauberC.LeontovichA.M.NeumanB.W.PenzarD.PerlmanS.PoonL.L.M.SamborskiyD.V.SidorovI.A.SolaI.ZiebuhrJ.The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.5202053654410.1038/s41564-020-0695-z32123347"/>
 <result pre="of tomorrowMol. Asp. Med.27200619310.1016/j.mam.2005.07.008 HaagmansB.L.KuikenT.MartinaB.E.FouchierR.A.RimmelzwaanG.F.Van AmerongenG.van RielD.De JongT.ItamuraS.ChanK.-H.Pegylated interferon-α protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaquesNat. Med.10200429029310.1038/nm100114981511 HabibzadehP.StonemanE.K.The"/>
 <result pre="AmerongenG.van RielD.De JongT.ItamuraS.ChanK.-H.Pegylated interferon-α protects type 1 pneumocytes against SARS" exact="coronavirus infection" post="in macaquesNat. Med.10200429029310.1038/nm100114981511 HabibzadehP.StonemanE.K.The novel coronavirus: a bird’s eye"/>
 <result pre="RielD.De JongT.ItamuraS.ChanK.-H.Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat. Med.10200429029310.1038/nm100114981511 HabibzadehP.StonemanE.K.The novel coronavirus: a bird’s eye"/>
 <result pre="bird’s eye viewInt. J. Occup. Environ. Med.1120206510.15171/ijoem.2020.192132020915 HarcourtB.H.JuknelieneD.KanjanahaluethaiA.BechillJ.SeversonK.M.SmithC.M.RotaP.A.BakerS.C.Identification of severe" exact="acute" post="respiratory syndrome coronavirus replicase products and characterization of papain-like"/>
 <result pre="eye viewInt. J. Occup. Environ. Med.1120206510.15171/ijoem.2020.192132020915 HarcourtB.H.JuknelieneD.KanjanahaluethaiA.BechillJ.SeversonK.M.SmithC.M.RotaP.A.BakerS.C.Identification of severe acute" exact="respiratory" post="syndrome coronavirus replicase products and characterization of papain-like protease"/>
 <result pre="viewInt. J. Occup. Environ. Med.1120206510.15171/ijoem.2020.192132020915 HarcourtB.H.JuknelieneD.KanjanahaluethaiA.BechillJ.SeversonK.M.SmithC.M.RotaP.A.BakerS.C.Identification of severe acute respiratory" exact="syndrome" post="coronavirus replicase products and characterization of papain-like protease activityJ."/>
 <result pre="protease activityJ. Virol.782004136001361210.1128/JVI.78.24.13600-13612.200415564471 HeL.QiY.RongX.JiangJ.YangQ.YamaharaJ.MurrayM.LiY.The Ayurvedic medicine Salacia oblonga attenuates diabetic" exact="renal fibrosis" post="in rats: suppression of angiotensin II/AT1 signalingEvid. Based Complement."/>
 <result pre="cellsBioRxiv202010.1101/2020.01.31.929042 HowardM.W.TravantyE.A.JeffersS.A.SmithM.WennierS.T.ThackrayL.B.HolmesK.V.Aromatic amino acids in the juxtamembrane domain of severe" exact="acute" post="respiratory syndrome coronavirus spike glycoprotein are important for receptor-dependent"/>
 <result pre="HowardM.W.TravantyE.A.JeffersS.A.SmithM.WennierS.T.ThackrayL.B.HolmesK.V.Aromatic amino acids in the juxtamembrane domain of severe acute" exact="respiratory" post="syndrome coronavirus spike glycoprotein are important for receptor-dependent virus"/>
 <result pre="amino acids in the juxtamembrane domain of severe acute respiratory" exact="syndrome" post="coronavirus spike glycoprotein are important for receptor-dependent virus entry"/>
 <result pre="SARS coronavirus infectionEmerg. Microbes. Infect.120121610.1038/emi.2012.26 JiangX.KandaT.NakamotoS.SaitoK.NakamuraM.WuS.HagaY.SasakiR.SakamotoN.ShirasawaH.The JAK2 inhibitor AZD1480 inhibits" exact="hepatitis" post="A virus replication in Huh7 cellsBiochem. Biophys. Res. Commun.458201590891210.1016/j.bbrc.2015.02.05825704089"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Military. Med. Res.72020410.1186/s40779-020-0233-6 KannanS.AliP.S.S.SheezaA.HemalathaK.COVID-19 (Novel Coronavirus 2019)–recent trendsEur."/>
 <result pre="virus entryJ. Virol.94202010.1128/JVI.01357-19 KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of"/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe"/>
 <result pre="syndrome coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem. Biophys. Res. Commun.323200426426810.1016/j.bbrc.2004.08.08515351731 KeyaertsE.VijgenL.PannecouqueC.Van"/>
 <result pre="coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem. Biophys. Res. Commun.323200426426810.1016/j.bbrc.2004.08.08515351731 KeyaertsE.VijgenL.PannecouqueC.Van DammeE.PeumansW.EgberinkH.BalzariniJ.Van"/>
 <result pre="entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem. Biophys. Res. Commun.323200426426810.1016/j.bbrc.2004.08.08515351731 KeyaertsE.VijgenL.PannecouqueC.Van DammeE.PeumansW.EgberinkH.BalzariniJ.Van RanstM.Plant"/>
 <result pre="inhibitors of coronaviruses by interfering with two targets in the" exact="viral" post="replication cycleAntivir. Res.75200717918710.1016/j.antiviral.2007.03.00317428553 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against"/>
 <result pre="Res.75200717918710.1016/j.antiviral.2007.03.00317428553 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob. Agents Chemother.5320093416342110.1128/AAC.01509-0819506054 KhanM.Y.KumarV.Mechanism &amp;amp; inhibition kinetics"/>
 <result pre="Tradit. Complement. Med.92019738410.1016/j.jtcme.2018.02.00130671369 KilianskiA.MielechA.M.DengX.BakerS.C.Assessing activity and inhibition of Middle East" exact="respiratory" post="syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensorsJ."/>
 <result pre="Complement. Med.92019738410.1016/j.jtcme.2018.02.00130671369 KilianskiA.MielechA.M.DengX.BakerS.C.Assessing activity and inhibition of Middle East respiratory" exact="syndrome" post="coronavirus papain-like and 3C-like proteases using luciferase-based biosensorsJ. Virol.872013119551196210.1128/JVI.02105-1323986593"/>
 <result pre="United States 2014–2017J. Clin. Virol.1012018525610.1016/j.jcv.2018.01.01929427907 KimI.LeeJ.E.KimK.H.LeeS.LeeK.MokJ.H.Successful treatment of suspected organizing" exact="pneumonia" post="in a patient with Middle East respiratory syndrome coronavirus"/>
 <result pre="of suspected organizing pneumonia in a patient with Middle East" exact="respiratory" post="syndrome coronavirus infection: a case reportJ. Thorac. Dis.8102016E119027867585 KonradR.EberleU.DangelA.TreisB.BergerA.BengsK.FingerleV.LieblB.AckermannN.SingA.Rapid"/>
 <result pre="suspected organizing pneumonia in a patient with Middle East respiratory" exact="syndrome" post="coronavirus infection: a case reportJ. Thorac. Dis.8102016E119027867585 KonradR.EberleU.DangelA.TreisB.BergerA.BengsK.FingerleV.LieblB.AckermannN.SingA.Rapid establishment"/>
 <result pre="originating in Wuhan, ChinaF1000Res920207210.12688/f1000research.22211.232117569 LeiP.FanB.MaoJ.WangP.Comprehensive analysis for diagnosis of novel" exact="coronavirus disease" post="(COVID-19) infectionJ. Inf. Secur.202010.1016/j.jinf.2020.03.016 LewinsohnD.M.BowdenR.A.MattsonD.CrawfordS.W.Phase I study of intravenous"/>
 <result pre="in Wuhan, ChinaF1000Res920207210.12688/f1000research.22211.232117569 LeiP.FanB.MaoJ.WangP.Comprehensive analysis for diagnosis of novel coronavirus" exact="disease" post="(COVID-19) infectionJ. Inf. Secur.202010.1016/j.jinf.2020.03.016 LewinsohnD.M.BowdenR.A.MattsonD.CrawfordS.W.Phase I study of intravenous"/>
 <result pre="Inf. Secur.202010.1016/j.jinf.2020.03.016 LewinsohnD.M.BowdenR.A.MattsonD.CrawfordS.W.Phase I study of intravenous ribavirin treatment of" exact="respiratory" post="syncytial virus pneumonia after marrow transplantationAntimicrob. Agents Chemother.401996255525578913463 Leyva-GradoV.H.BehzadiM.A.Overview"/>
 <result pre="I study of intravenous ribavirin treatment of respiratory syncytial virus" exact="pneumonia" post="after marrow transplantationAntimicrob. Agents Chemother.401996255525578913463 Leyva-GradoV.H.BehzadiM.A.Overview of current therapeutics"/>
 <result pre="Chemother.401996255525578913463 Leyva-GradoV.H.BehzadiM.A.Overview of current therapeutics and novel candidates against influenza," exact="respiratory" post="syncytial virus and Middle East respiratory syndrome coronavirus infectionsFronti."/>
 <result pre="novel candidates against influenza, respiratory syncytial virus and Middle East" exact="respiratory" post="syndrome coronavirus infectionsFronti. Microbiol.102019132710.3389/fmicb.2019.01327 LiG.ClercqE.Therapeutic options for the 2019"/>
 <result pre="candidates against influenza, respiratory syncytial virus and Middle East respiratory" exact="syndrome" post="coronavirus infectionsFronti. Microbiol.102019132710.3389/fmicb.2019.01327 LiG.ClercqE.Therapeutic options for the 2019 novel"/>
 <result pre="coronavirus (2019-nCoV)Nat. Rev. Drug Discov.19202014491415010.1038/d41573-020-00016-0 LiZ.HeW.LanY.ZhaoK.LvX.LuH.DingN.ZhangJ.ShiJ.ShanC.The evidence of porcine hemagglutinating" exact="encephalomyelitis" post="virus induced nonsuppurative encephalitis as the cause of death"/>
 <result pre="Discov.19202014491415010.1038/d41573-020-00016-0 LiZ.HeW.LanY.ZhaoK.LvX.LuH.DingN.ZhangJ.ShiJ.ShanC.The evidence of porcine hemagglutinating encephalomyelitis virus induced nonsuppurative" exact="encephalitis" post="as the cause of death in pigletsPeer. J.42016244310.7717/peerj.2443 LiY.BaiW.HashikawaT.The"/>
 <result pre="of SARS-CoV2 may be at least partially responsible for the" exact="respiratory" post="failure of COVID-19 patientsJ. Med. Virol.202010.1002/jmv.25728 LinS.ShenR.HeJ.LiX.GuoX.Molecular Modeling Evaluation"/>
 <result pre="of the Binding Effect of Ritonavir, Lopinavir and Darunavir to" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 Proteases. BioRxiv202010.1101/2020.01.31.929695 LiouC.J.ChengC.Y.YehK.W.WuY.H.HuangW.C.Protective effects"/>
 <result pre="the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Proteases. BioRxiv202010.1101/2020.01.31.929695 LiouC.J.ChengC.Y.YehK.W.WuY.H.HuangW.C.Protective effects of"/>
 <result pre="Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Proteases. BioRxiv202010.1101/2020.01.31.929695 LiouC.J.ChengC.Y.YehK.W.WuY.H.HuangW.C.Protective effects of casticin"/>
 <result pre="Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Proteases. BioRxiv202010.1101/2020.01.31.929695 LiouC.J.ChengC.Y.YehK.W.WuY.H.HuangW.C.Protective effects of casticin from"/>
 <result pre="Proteases. BioRxiv202010.1101/2020.01.31.929695 LiouC.J.ChengC.Y.YehK.W.WuY.H.HuangW.C.Protective effects of casticin from vitex trifolia alleviate" exact="eosinophilic" post="airway inflammation and oxidative stress in a murine asthma"/>
 <result pre="alleviate eosinophilic airway inflammation and oxidative stress in a murine" exact="asthma" post="modelFront. Pharma col.9201863510.3389/fphar.2018.00635 LippiG.SimundicA.M.PlebaniM.Potential preanalytical and analytical vulnerabilities in"/>
 <result pre="LippiG.SimundicA.M.PlebaniM.Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of" exact="coronavirus disease" post="2019 (COVID-19)Clin. Chem. Lab. Med.202010.1515/cclm-2020-0285 LiuD.X.FungT.S.ChongK.K.-L.ShuklaA.HilgenfeldR.Accessory proteins of SARS-CoV"/>
 <result pre="preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus" exact="disease" post="2019 (COVID-19)Clin. Chem. Lab. Med.202010.1515/cclm-2020-0285 LiuD.X.FungT.S.ChongK.K.-L.ShuklaA.HilgenfeldR.Accessory proteins of SARS-CoV"/>
 <result pre="of coronavirus spike proteins and host ACE2 receptors predict potential" exact="intermediate" post="hosts of SARS-CoV-2J. Med. Virol.202010.1002/jmv.25726 Li-WeberM.New therapeutic aspects of"/>
 <result pre="extract as hyaluronidase, elastase and matrix-metalloproteinase-1 inhibitorIndian. J. pharmacol.44201258410.4103/0253-7613.10038123112418 MaloirQ.GhysenK.LouisR.GuiotJ.Acute" exact="respiratory" post="distress revealing antisynthetase syndromeRev. Med. Liege73201837037530113776 ManniM.L.RobinsonK.M.AlcornJ.F.A tale of"/>
 <result pre="Liege73201837037530113776 ManniM.L.RobinsonK.M.AlcornJ.F.A tale of two cytokines: IL-17 and IL-22 in" exact="asthma" post="and infectionExpert. Rev. Respir. Med.82014254210.1586/17476348.2014.85416724325586 MarchK.BogatchevaN.Use of asc and"/>
 <result pre="of antiviral additivity with alpha interferonAntimicrob. Agents Chemother.44200085986610.1128/aac.44.4.859-866.200010722482 MatsudaK.ParkC.SundenY.KimuraT.OchiaiK.KidaH.UmemuraT.The vagus" exact="nerve" post="is one route of transneural invasion for intranasally inoculated"/>
 <result pre="Pathol.41200410110710.1354/vp.41-2-10115017022 MatthewA.Lost Smell and Taste Hint COVID-19 Can Target the" exact="Nervous System." post="The Scientist. Published on 24th March, 20202020 McIntoshK.KurachekS.C.CairnsL.M.BurnsJ.C.GoodspeedB.Treatment of"/>
 <result pre="System. The Scientist. Published on 24th March, 20202020 McIntoshK.KurachekS.C.CairnsL.M.BurnsJ.C.GoodspeedB.Treatment of" exact="respiratory" post="viral infection in an immunodeficient infant with ribavirin aerosolAm."/>
 <result pre="The Scientist. Published on 24th March, 20202020 McIntoshK.KurachekS.C.CairnsL.M.BurnsJ.C.GoodspeedB.Treatment of respiratory" exact="viral infection" post="in an immunodeficient infant with ribavirin aerosolAm. J, Dis."/>
 <result pre="Scientist. Published on 24th March, 20202020 McIntoshK.KurachekS.C.CairnsL.M.BurnsJ.C.GoodspeedB.Treatment of respiratory viral" exact="infection" post="in an immunodeficient infant with ribavirin aerosolAm. J, Dis."/>
 <result pre="MulanguS.DoddL.E.DaveyR.T.Jr.Tshiani MbayaO.ProschanM.MukadiD.Lusakibanza ManzoM.NzoloD.Tshomba OlomaA.IbandaA.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN. Engl. J. Med.38120192293230310.1056/NEJMoa191099331774950 NairR.HIV-1 reverse transcriptase inhibition by"/>
 <result pre="flavonoids in relation to anti-HIV activityJ. Cell. Mol. Biol.1020125359 Nieto-TorresJ.L.Verdiá-BáguenaC.Jimenez-GuardeñoJ.M.Regla-NavaJ.A.Castaño-RodriguezC.Fernandez-DelgadoR.TorresJ.AguilellaV.M.EnjuanesL.Severe" exact="acute" post="respiratory syndrome coronavirus E protein transports calcium ions and"/>
 <result pre="in relation to anti-HIV activityJ. Cell. Mol. Biol.1020125359 Nieto-TorresJ.L.Verdiá-BáguenaC.Jimenez-GuardeñoJ.M.Regla-NavaJ.A.Castaño-RodriguezC.Fernandez-DelgadoR.TorresJ.AguilellaV.M.EnjuanesL.Severe acute" exact="respiratory" post="syndrome coronavirus E protein transports calcium ions and activates"/>
 <result pre="relation to anti-HIV activityJ. Cell. Mol. Biol.1020125359 Nieto-TorresJ.L.Verdiá-BáguenaC.Jimenez-GuardeñoJ.M.Regla-NavaJ.A.Castaño-RodriguezC.Fernandez-DelgadoR.TorresJ.AguilellaV.M.EnjuanesL.Severe acute respiratory" exact="syndrome" post="coronavirus E protein transports calcium ions and activates the"/>
 <result pre="glabra on HSP90 gene expression and apoptosis in the HT-29" exact="colon cancer" post="cell lineAsian Pac. J. Cancer Prev.2011201511610.7314/APJCP.2015.16.18.8563 OlivieriF.PrasadV.ValbonesiP.SrivastavaS.Ghosal-ChowdhuryP.BarbieriL.BolognesiA.StirpeF.A systemic antiviral"/>
 <result pre="on HSP90 gene expression and apoptosis in the HT-29 colon" exact="cancer" post="cell lineAsian Pac. J. Cancer Prev.2011201511610.7314/APJCP.2015.16.18.8563 OlivieriF.PrasadV.ValbonesiP.SrivastavaS.Ghosal-ChowdhuryP.BarbieriL.BolognesiA.StirpeF.A systemic antiviral"/>
 <result pre="apoptosis in the HT-29 colon cancer cell lineAsian Pac. J." exact="Cancer" post="Prev.2011201511610.7314/APJCP.2015.16.18.8563 OlivieriF.PrasadV.ValbonesiP.SrivastavaS.Ghosal-ChowdhuryP.BarbieriL.BolognesiA.StirpeF.A systemic antiviral resistance-inducing protein isolated from Clerodendrum"/>
 <result pre="HT-29 colon cancer cell lineAsian Pac. J. Cancer Prev.2011201511610.7314/APJCP.2015.16.18.8563 OlivieriF.PrasadV.ValbonesiP.SrivastavaS.Ghosal-ChowdhuryP.BarbieriL.BolognesiA.StirpeF.A" exact="systemic" post="antiviral resistance-inducing protein isolated from Clerodendrum inerme Gaertn. Is"/>
 <result pre="(ribosome-inactivating protein)FEBS Lett.39619961321348914973 OtakeT.MoriH.MorimotoM.UebaN.SutardjoS.KusumotoI.T.HattoriM.NambaT.Screening of Indonesian plant extracts for anti-human" exact="immunodeficiency" post="virus—type 1 (HIV-1) activityPhytother. Res.91995610 PanP.P.ZhangQ.T.LeF.ZhengY.M.JinF.Angiotensin-converting enzymes play a"/>
 <result pre="Pharm. Bioallied. Sci.33201143510.4103/0975-7406.8446221966166 ParasuramanS.ThingG.S.DhanarajS.A.Polyherbal formulation: concept of ayurvedaPharmacogn. Rev.820147310.4103/0973-7847.13422925125878 PeirisJ.GuanY.YuenK.Severe" exact="acute" post="respiratory syndromeNat. Med.102004S88S9710.1038/nm114315577937 PetersH.L.JochmansD.de WildeA.H.PosthumaC.C.SnijderE.J.NeytsJ.Seley-RadtkeK.L.Design, synthesis and evaluation of"/>
 <result pre="Bioallied. Sci.33201143510.4103/0975-7406.8446221966166 ParasuramanS.ThingG.S.DhanarajS.A.Polyherbal formulation: concept of ayurvedaPharmacogn. Rev.820147310.4103/0973-7847.13422925125878 PeirisJ.GuanY.YuenK.Severe acute" exact="respiratory" post="syndromeNat. Med.102004S88S9710.1038/nm114315577937 PetersH.L.JochmansD.de WildeA.H.PosthumaC.C.SnijderE.J.NeytsJ.Seley-RadtkeK.L.Design, synthesis and evaluation of a"/>
 <result pre="to clinical diagnosticsInfect. Genet. Evo.79202010421110.1016/j.meegid.2020.104211 PrathapanA.VineethaV.AbhilashP.RaghuK.Boerhaaviadiffusa L. attenuates angiotensin II-induced" exact="hypertrophy" post="in H9c2 cardiac myoblast cells via modulating oxidative stress"/>
 <result pre="of traditional Indian medicines (TIM)J. AOAC Int.102201997797810.5740/jaoacint.18-037630558694 QueT.WongV.YuenK.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="traditional Indian medicines (TIM)J. AOAC Int.102201997797810.5740/jaoacint.18-037630558694 QueT.WongV.YuenK.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
 <result pre="Indian medicines (TIM)J. AOAC Int.102201997797810.5740/jaoacint.18-037630558694 QueT.WongV.YuenK.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
 <result pre="Complement. Altern. Med.4200731933710.4314/ajtcam.v4i3.31226 RazonableR.R.Antiviral drugs for viruses other than human" exact="immunodeficiency" post="virusMayo Clin. Proc.8620111009102610.4065/mcp.2011.030921964179 RegeA.ChowdharyA.S.Evaluation of Ocimum sanctum and Tinospora"/>
 <result pre="Pharm. Sci. Rev. Res.252014315318 RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet3952020303110.1016/S0140-6736(20)30304-431908280 RossignolJ.-F.Nitazoxanide, a new drug candidate for the"/>
 <result pre="Sci. Rev. Res.252014315318 RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet3952020303110.1016/S0140-6736(20)30304-431908280 RossignolJ.-F.Nitazoxanide, a new drug candidate for the treatment"/>
 <result pre="a new drug candidate for the treatment of Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect. Public. Health.9201622723010.1016/j.jiph.2016.04.00127095301 RudraS.KalraA.KumarA.JoeW.Utilization of alternative systems"/>
 <result pre="new drug candidate for the treatment of Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect. Public. Health.9201622723010.1016/j.jiph.2016.04.00127095301 RudraS.KalraA.KumarA.JoeW.Utilization of alternative systems of"/>
 <result pre="and activates NLRP3 inflammasomesCell. Death. Discov.5201911210.1038/s41420-019-0181-7 ShiF.YuQ.HuangW.TanC.2019 novel coronavirus (COVID-19)" exact="pneumonia" post="with hemoptysis as the initial symptom: CT and clinical"/>
 <result pre="CT and clinical featuresKorean J. Radiol.202010.1148/radiol.2020200490 ShiratoK.YanoT.SenbaS.AkachiS.KobayashiT.NishinakaT.NotomiT.MatsuyamaS.Detection of Middle East" exact="respiratory" post="syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP)Virol."/>
 <result pre="and clinical featuresKorean J. Radiol.202010.1148/radiol.2020200490 ShiratoK.YanoT.SenbaS.AkachiS.KobayashiT.NishinakaT.NotomiT.MatsuyamaS.Detection of Middle East respiratory" exact="syndrome" post="coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP)Virol. J.11201413910.1186/1743-422X-11-13925103205"/>
 <result pre="isothermal amplification (RT-LAMP)Virol. J.11201413910.1186/1743-422X-11-13925103205 SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent severe" exact="acute" post="respiratory syndrome coronavirus entryProc. Natl. Acad. Sci.102332005118761188116081529 SimmonsG.ZmoraP.GiererS.HeurichA.PöhlmannS.Proteolytic activation"/>
 <result pre="amplification (RT-LAMP)Virol. J.11201413910.1186/1743-422X-11-13925103205 SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent severe acute" exact="respiratory" post="syndrome coronavirus entryProc. Natl. Acad. Sci.102332005118761188116081529 SimmonsG.ZmoraP.GiererS.HeurichA.PöhlmannS.Proteolytic activation of"/>
 <result pre="(RT-LAMP)Virol. J.11201413910.1186/1743-422X-11-13925103205 SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent severe acute respiratory" exact="syndrome" post="coronavirus entryProc. Natl. Acad. Sci.102332005118761188116081529 SimmonsG.ZmoraP.GiererS.HeurichA.PöhlmannS.Proteolytic activation of the"/>
 <result pre="SiuY.TeohK.LoJ.ChanC.KienF.EscriouN.TsaoS.NichollsJ.AltmeyerR.PeirisJ.The M, E, and N structural proteins of the severe" exact="acute" post="respiratory syndrome coronavirus are required for efficient assembly, trafficking,"/>
 <result pre="M, E, and N structural proteins of the severe acute" exact="respiratory" post="syndrome coronavirus are required for efficient assembly, trafficking, and"/>
 <result pre="E, and N structural proteins of the severe acute respiratory" exact="syndrome" post="coronavirus are required for efficient assembly, trafficking, and release"/>
 <result pre="efficient assembly, trafficking, and release of virus-like particlesJ. Virol.822008113181133010.1128/JVI.01052-0818753196 SiuK.L.YuenK.S.Castaño-RodriguezC.YeZ.W.YeungM.L.FungS.Y.YuanS.ChanC.P.YuenK.Y.EnjuanesL.Severe" exact="acute" post="respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome"/>
 <result pre="assembly, trafficking, and release of virus-like particlesJ. Virol.822008113181133010.1128/JVI.01052-0818753196 SiuK.L.YuenK.S.Castaño-RodriguezC.YeZ.W.YeungM.L.FungS.Y.YuanS.ChanC.P.YuenK.Y.EnjuanesL.Severe acute" exact="respiratory" post="syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by"/>
 <result pre="trafficking, and release of virus-like particlesJ. Virol.822008113181133010.1128/JVI.01052-0818753196 SiuK.L.YuenK.S.Castaño-RodriguezC.YeZ.W.YeungM.L.FungS.Y.YuanS.ChanC.P.YuenK.Y.EnjuanesL.Severe acute respiratory" exact="syndrome" post="coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting"/>
 <result pre="Sphaeranthus indicus inhibits expression of VCAM1 and ICAM1, and slows" exact="atherosclerosis" post="progression independent of lipid changesNutr. Metab.1220152010.1186/s12986-015-0018-1 StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.RichardsonP.COVID-19: combining antiviral"/>
 <result pre="novel coronavirus: implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccineCell. Mol. Immunol.20201810.1038/s41423-020-0400-431611651 TalbotP.J.ÉkandéS.CashmanN.R.MounirS.StewartJ.N.Neurotropism of human"/>
 <result pre="Mol. Immunol.20201810.1038/s41423-020-0400-431611651 TalbotP.J.ÉkandéS.CashmanN.R.MounirS.StewartJ.N.Neurotropism of human coronavirus 229ECoronaviruses1994339346 TanE.L.OoiE.E.LinC.Y.TanH.C.LingA.E.LimB.StantonL.W.Inhibition of SARS" exact="coronavirus infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458110.3201/eid1004.03045815200845"/>
 <result pre="Immunol.20201810.1038/s41423-020-0400-431611651 TalbotP.J.ÉkandéS.CashmanN.R.MounirS.StewartJ.N.Neurotropism of human coronavirus 229ECoronaviruses1994339346 TanE.L.OoiE.E.LinC.Y.TanH.C.LingA.E.LimB.StantonL.W.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458110.3201/eid1004.03045815200845"/>
 <result pre="antiviral activitiesPharm. Biol.47200942242910.1080/13880200902800196 VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 WalkerL.M.BurtonD.R.Passive immunotherapy of viral infections: ‘super-antibodies’"/>
 <result pre="activitiesPharm. Biol.47200942242910.1080/13880200902800196 VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 WalkerL.M.BurtonD.R.Passive immunotherapy of viral infections: ‘super-antibodies’"/>
 <result pre="of SARS coronavirus infection and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 WalkerL.M.BurtonD.R.Passive immunotherapy of" exact="viral" post="infections: ‘super-antibodies’ enter the frayNat. Rev. Immunol.18201829710.1038/nri.2017.14829379211 WallsA.C.ParkY.J.TortoriciM.A.WallA.McGuireA.T.VeeslerD.Structure, function,"/>
 <result pre="WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected" exact="pneumonia" post="in Wuhan, ChinaJama32320201061106910.1001/jama.2020.1585 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="(WHO)Novel coronavirus (2019-nCoV) situation reporthttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports2020 World Health Organization (WHO)Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) – the Kingdom of Saudi Arabiahttps://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/2020"/>
 <result pre="coronavirus (2019-nCoV) situation reporthttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports2020 World Health Organization (WHO)Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) – the Kingdom of Saudi Arabiahttps://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/2020 World"/>
 <result pre="Saudi Arabiahttps://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/2020 World Health Organization (WHO)Surveillance case definitions for human" exact="infection" post="with novel coronavirus (nCoV)https://apps.who.int/iris/handle/10665/3303762020 WuZ.McGooganJ.M.Characteristics of and important lessons"/>
 <result pre="novel coronavirus (nCoV)https://apps.who.int/iris/handle/10665/3303762020 WuZ.McGooganJ.M.Characteristics of and important lessons from the" exact="coronavirus disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="coronavirus (nCoV)https://apps.who.int/iris/handle/10665/3303762020 WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA202010.1001/jama.2020.2648 WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.Genome composition and divergence of the"/>
 <result pre="Mol. Imaging20201610.1007/s00259-020-04735-9 YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422 YangY.XiongZ.ZhangS.YanY.NguyenJ.NgB.LuH.BrendeseJ.YangF.WangH.Bcl-xL inhibits T-cell apoptosis"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422 YangY.XiongZ.ZhangS.YanY.NguyenJ.NgB.LuH.BrendeseJ.YangF.WangH.Bcl-xL inhibits T-cell apoptosis"/>
 <result pre="induced by expression of SARS coronavirus E protein in the" exact="absence of" post="growth factorsBiochem. J.392200513514310.1042/BJ2005069816048439 YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of lopinavir therapy"/>
 <result pre="reference for coronavirus disease-19 treatment optionJ. Med. Virol.202010.1002/jmv.25729 YarnellE.Herbs for" exact="viral" post="respiratory infectionsAltern. Complement. Ther.242018354310.1089/act.2017.29150.eya YinY.WunderinkR.G.MERS, SARS and other coronaviruses"/>
 <result pre="for coronavirus disease-19 treatment optionJ. Med. Virol.202010.1002/jmv.25729 YarnellE.Herbs for viral" exact="respiratory" post="infectionsAltern. Complement. Ther.242018354310.1089/act.2017.29150.eya YinY.WunderinkR.G.MERS, SARS and other coronaviruses as"/>
 <result pre="ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN. Engl. J. Med.36720121814182010.1056/NEJMoa121172123075143 ZhangL.LinD.SunX.CurthU.DrostenC.SauerheringL.BeckerS.RoxK.HilgenfeldR.Crystal structure of"/>
 <result pre="in SARS-CoV-2 compared to SARS-CoVCell. Mol. Immunol.1720201310.1038/s41423-020-0385-z31611651 ZhengY.MaY.ZhangJ.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat. Rev. Cardiol.202010.1038/s41569-020-0360-5 ZhouX.HuangF.XuL.LinZ.de VrijF.Ayo-MartinA.C.van der KroegM.ZhaoM.YinY.WangW.Hepatitis E virus"/>
 <result pre="out this review process. The Authors wish to thank the" exact="Advanced" post="Level State Biotech Hub (BT/04/NE/2009 Dt.29.082014), Mizoram University, Aizawl"/>
</results>
